Background: Mucoepidermoid carcinoma (MEC) showing Warthin’s tumor (WT)-like features is a low-grade malignancy which should be differentiated from WT. Morphological features may be distinctly different in each case, causing diagnostic difficulties. Case Presentation: Three cases were presented and discussed with their morphologies. All cases that presented with a mass in the parotid gland went to parotidectomy, and all had preoperative fine-needle aspirations (FNAs). Case 1 was a 16-year-old female; FNA was suggestive of WT and initially interpreted as WT histologically. Case 2 was a 27-year-old male; FNA was interpreted as noninformative due to the presence of cyst fluid only. Case 3 was a 53-year-old male and cytologically was found to be suspicious for MEC which contained squamous and goblet cells on a mucoid background. On histopathological examination, case 2 and case 3 were morphologically consistent with low-grade MEC with WT-like features. Prominent lymphoid stroma and the cystic pattern were the characters of these tumors. Case 1 had the classical WT appearance with some mucinous and squamous metaplasia which could only be interpreted as MEC after the detection of MAML2 rearrangement by FISH. The other 2 showed either focal or relatively diffuse usual low-grade MEC findings, and case 3 was also confirmed by MAML2 rearrangement. Conclusion: Cytological and histopathological features revealed a spectrum. Differentiating WT-like MECs from ordinary WTs may be challenging. On the one end of the spectrum, they may look very much like WT, and on the other end, even though usual MEC features are present, still, WT-like appearance may pose diagnostic difficulty. Showing MAML2 rearrangement in these cases is very helpful. The presence of mucinous and squamous cells in an otherwise WT-like looking tumor should be alarming for MEC, and if possible, each case should be analyzed for MAML2 rearrangement.

1.
Yorita
K
,
Nakagawa
H
,
Miyazaki
K
,
Fukuda
J
,
Ito
S
,
Kosai
M
.
Infarcted Warthin tumor with mucoepidermoid carcinoma-like metaplasia: a case report and review of the literature
.
J Med Case Rep
.
2019 Jan
;
13
(
1
):
12
. .
2.
Di Palma
S
,
Simpson
RH
,
Skálová
A
,
Michal
M
.
Metaplastic (infarcted) Warthin’s tumour of the parotid gland: a possible consequence of fine needle aspiration biopsy
.
Histopathology
.
1999 Nov
;
35
(
5
):
432
8
. .
3.
Orell
SR
,
Nettle
WJ
.
Fine needle aspiration biopsy of salivary gland tumours. Problems and pitfalls
.
Pathology
.
1988 Oct
;
20
(
4
):
332
7
. .
4.
Hang
JF
,
Shum
CH
,
Ali
SZ
,
Bishop
JA
.
Cytological features of the Warthin-like variant of salivary mucoepidermoid carcinoma
.
Diagn Cytopathol
.
2017 Dec
;
45
(
12
):
1132
6
. .
5.
Daoud
EV
,
McLean-Holden
AC
,
Pfeifer
CM
,
Timmons
CF
,
Oliai
BR
,
Bishop
JA
.
Pediatric Warthin-like mucoepidermoid carcinoma: report of two cases with one persistent/recurrent as conventional mucoepidermoid carcinoma
.
Head Neck Pathol
.
2020 Dec
;
14
(
4
):
923
8
. .
6.
Zhang
X
,
Baloch
ZW
,
Cooper
K
,
Zhang
PJ
,
Puthiyaveettil
R
,
LiVolsi
VA
.
The significance of mucinous metaplasia in Warthin tumor: a frequent occurrence and potential pitfall
.
Hum Pathol
.
2020 May
;
99
:
13
26
. .
7.
Ishibashi
K
,
Ito
Y
,
Masaki
A
,
Fujii
K
,
Beppu
S
,
Sakakibara
T
,
Warthin-like mucoepidermoid carcinoma: a combined study of fluorescence in situ hybridization and whole-slide imaging
.
Am J Surg Pathol
.
2015 Nov
;
39
(
11
):
1479
87
. .
8.
Zhang
D
,
Liao
X
,
Tang
Y
,
Meyer
RG
,
Van Dyke
DL
,
Liu
X
,
Warthin-like mucoepidermoid carcinoma of the parotid gland: unusual morphology and diagnostic pitfalls
.
Anticancer Res
.
2019 Jun
;
39
(
6
):
3213
7
.
9.
Zhang
C
,
Gu
T
,
Hu
Y
,
Sun
J
,
Xia
R
,
Tian
Z
,
Reevaluation of salivary lymphadenoma: a subgroup identified as Warthin-like mucoepidermoid carcinoma following molecular investigation for MAML2 rearrangement
.
Arch Pathol Lab Med
.
2021 Jun
;
145
(
6
):
744
52
.
10.
Balasubiramaniyan
V
,
Sultania
M
,
Sable
M
,
Muduly
D
,
Kar
M
.
Warthin-like mucoepidermoid carcinoma of the parotid gland: a diagnostic and therapeutic dilemma
.
Autops Case Rep
.
2019 Sep 30
;
9
(
4
):
e2019122
. .
11.
Martins
C
,
Cavaco
B
,
Tonon
G
,
Kaye
FJ
,
Soares
J
,
Fonseca
I
.
A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin’s tumor of salivary glands
.
J Mol Diagn
.
2004 Aug
;
6
(
3
):
205
10
. .
12.
Skálová
A
,
Vanecek
T
,
Simpson
RH
,
Vazmitsel
MA
,
Majewska
H
,
Mukensnabl
P
,
CRTC1-MAML2 and CRTC3-MAML2 fusions were not detected in metaplastic Warthin tumor and metaplastic pleomorphic adenoma of salivary glands
.
Am J Surg Pathol
.
2013 Nov
;
37
(
11
):
1743
50
.
13.
Seethala
RR
,
Dacic
S
,
Cieply
K
,
Kelly
LM
,
Nikiforova
MN
.
A reappraisal of the MECT1/MAML2 translocation in salivary mucoepidermoid carcinomas
.
Am J Surg Pathol
.
2010 Aug
;
34
(
8
):
1106
21
. .
14.
Fehr
A
,
Röser
K
,
Belge
G
,
Löning
T
,
Bullerdiek
J
.
A closer look at Warthin tumors and the t(11;19)
.
Cancer Genet Cytogenet
.
2008 Jan
;
180
(
2
):
135
9
. .
15.
Bieńkowski
M
,
Kunc
M
,
Iliszko
M
,
Kuźniacka
A
,
Studniarek
M
,
Biernat
W
.
MAML2 rearrangement as a useful diagnostic marker discriminating between Warthin tumour and Warthin-like mucoepidermoid carcinoma
.
Virchows Arch
.
2020 Sep
;
477
(
3
):
393
400
. .
16.
García
JJ
,
Hunt
JL
,
Weinreb
I
,
McHugh
JB
,
Barnes
EL
,
Cieply
K
,
Fluorescence in situ hybridization for detection of MAML2 rearrangements in oncocytic mucoepidermoid carcinomas: utility as a diagnostic test
.
Hum Pathol
.
2011 Dec
;
42
(
12
):
2001
9
.
17.
Akaev
I
,
Yeoh
CC
,
Brennan
PA
,
Rahimi
S
.
Low grade parotid mucoepidermoid carcinoma with tumour associated lymphoid proliferation (“Warthin-like”) and CRTC1-MAML2 fusion transcript: definitive diagnosis with molecular investigation only
.
Oral Oncol
.
2018 May
;
80
:
98
9
. .
18.
Bell
D
,
Luna
MA
,
Weber
RS
,
Kaye
FJ
,
El-Naggar
AK
.
CRTC1/MAML2 fusion transcript in Warthin’s tumor and mucoepidermoid carcinoma: evidence for a common genetic association
.
Genes Chromosomes Cancer
.
2008 Apr
;
47
(
4
):
309
14
. .
19.
Heatley
N
,
Harrington
KJ
,
Thway
K
.
Warthin tumor-like mucoepidermoid carcinoma
.
Int J Surg Pathol
.
2018 Feb
;
26
(
1
):
31
3
. .
20.
Bishop
JA
,
Cowan
ML
,
Shum
CH
,
Westra
WH
.
MAML2 rearrangements in variant forms of mucoepidermoid carcinoma: ancillary diagnostic testing for the ciliated and Warthin-like variants
.
Am J Surg Pathol
.
2018 Jan
;
42
(
1
):
130
6
. .
21.
Okabe
M
,
Miyabe
S
,
Nagatsuka
H
,
Terada
A
,
Hanai
N
,
Yokoi
M
,
MECT1-MAML2 fusion transcript defines a favorable subset of mucoepidermoid carcinoma
.
Clin Cancer Res
.
2006 Jul
;
12
(
13
):
3902
7
.
22.
Cipriani
NA
,
Lusardi
JJ
,
McElherne
J
,
Pearson
AT
,
Olivas
AD
,
Fitzpatrick
C
,
Mucoepidermoid carcinoma: a comparison of histologic grading systems and relationship to MAML2 rearrangement and prognosis
.
Am J Surg Pathol
.
2019 Jul
;
43
(
7
):
885
97
.
23.
Bullerdiek
J
,
Haubrich
J
,
Meyer
K
,
Bartnitzke
S
.
Translocation t(11;19)(q21;p13.1) as the sole chromosome abnormality in a cystadenolymphoma (Warthin’s tumor) of the parotid gland
.
Cancer Genet Cytogenet
.
1988 Oct
;
35
(
1
):
129
32
. .
24.
Flezar
M
,
Pogacnik
A
.
Warthin’s tumour: unusual vs. common morphological findings in fine needle aspiration biopsies
.
Cytopathology
.
2002 Aug
;
13
(
4
):
232
41
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.